“We are excited to have Daniel Mallett, DPM join this important study as the third investigator and the second podiatrist. It is important to evaluate the product and subungual topical procedure in patients visiting both podiatrists and dermatologists." ~ Mark Taylor, Hallux Inc. CEO
LAGUNA HILLS, California (PRWEB) September 22, 2022
Hallux Inc, a clinical stage pharmaceutical company, today announced that Front Range Foot and Ankle Clinic in Parker, Colorado has begun screening patients for enrollment into HSG-201, its 52-week clinical study evaluating Hallux Subungual Gel (HSG) for the treatment of onychomycosis (toenail fungus).
Hallux CEO Mark Taylor said, “We are excited to have Daniel Mallett, DPM join this important study. Dr. Mallet is the third investigator in our study, and the second podiatrist. It is important to evaluate the product and topical procedure in patients visiting both podiatrists and dermatologists, as their age, medical history, and disease severity can differ significantly. As the Sponsor, we are fortunate to have clinical experts like Dr. Mallet join dermatologist Terry Jones of J&S Studies in College Station, Texas and foot and ankle surgeon Dr. Lewis Freed of OrthoArizona in Mesa, Arizona to investigate the efficacy, safety, and pharmacokinetics of HSG in the treatment of mycologically confirmed onychomycosis patients enrolled from their respective communities."
Hallux is a clinical stage pharmaceutical company focused on developing a new terbinafine subungual dosage form and direct-to-nail bed topical route of administration for treating onychomycosis (toenail fungus). Hallux’s goal is to provide high effectiveness and safety for chronic onychomycosis patients around the world. In the United States, Hallux is conducting the Phase 2a HSG-201 clinical study in podiatry clinics through site manager Physician’s Research Group LLC, a specialist in podiatric and dermatologic clinical research.